OncoMatch/Clinical Trials/NCT04361708
Safety of Combining Irinotecan With 5-FU, Leucovorin/Folinic Acid, Oxaliplatin, and Docetaxel Chemotherapies
Is NCT04361708 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies multiple treatments for pancreatic adenocarcinoma.
Treatment: Oxaliplatin · Docetaxel · Leucovorin · Irinotecan · 5-Fluorouracil — The purpose of the proposed study is to establish the safety of combining irinotecan chemotherapy with 5-FU, leucovorin/folinic acid, oxaliplatin, and docetaxel (abbreviated as the I-FLOAT study of gFOLFOXIRITAX) chemotherapies (leucovorin/folinic acid is a vitamin to make 5-FU work well).
Check if I qualifyExtracted eligibility criteria
Cancer type
Pancreatic Cancer
Gastric Cancer
Esophageal Carcinoma
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: radiation therapy
Prior radiation therapy for any cancer
Cannot have received: chemotherapy for metastatic disease
Exception: Recurrence of disease within 6 months of perioperative chemotherapy are eligible if other eligibility criteria are met
Prior chemotherapy for metastatic disease
Lab requirements
Blood counts
Absolute neutrophil count (ANC) = 1500/uL; Hemoglobin > 9g/dL (transfusion permitted with stability for > 1 week); Platelets > 100,000/uL
Kidney function
Creatinine = 1.5 mg/dL
Liver function
Total bilirubin = 1.5 mg/dL; AST and ALT = 2.5 X upper limit of normal; alkaline phosphatase = 2.5 X upper limit of normal, unless bone metastasis is present in the absence of liver metastasis. AST and ALT = 5 X upper limit of normal if hepatic metastases are present.
Adequate organ function, as defined by each of the following: Absolute neutrophil count (ANC) = 1500/uL Hemoglobin > 9g/dL (transfusion permitted with stability for > 1 week) Platelets > 100,000/uL Total bilirubin = 1.5 mg/dL AST and ALT = 2.5 X upper limit of normal; alkaline phosphatase = 2.5 X upper limit of normal, unless bone metastasis is present in the absence of liver metastasis. AST and ALT = 5 X upper limit of normal if hepatic metastases are present. Creatinine = 1.5 mg/dL
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- The University of Chicago · Chicago, Illinois
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify